Objective: The International Society of Hypertension (ISH) recommended lower blood pressure (BP) targets in hypertension management using an individualized treatment strategy (ITS) and referral to a hypertension specialist if target is not reached within 6 months. This study was designed to test the hypothesis that in general practice the ITS may fail to achieve target BP within 6 months in a high proportion of patients, whereas a stepwise treatment strategy (STS) (as in the outcome studies, e.g. the HOT study) may be superior.
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The aim of this study was to determine whether HMG-CoA reductase inhibitors (statins) are used in line with current recommendations for the prevention of coronary heart disease and to identify factors which determine patient response.
Patients attending the Cardiovascular Risk Clinic in Aberdeen were prospectively screened for statin use. Gender, age, current statin and dose, treatment start date, pre-and most recent post-treatment lipid measurements were recorded.
407 patients receiving a statin were identified of whom 355 had a complete lipid data set. 194 (54.6%) failed to meet the recommended total cholesterol (TC) target of Ͻ5.0mmol/l. Failure to meet target levels was associated with a significantly higher pre-treatment TC (7.66Ϯ1.37 vs 6.61Ϯ1.13mmol/l, pϽ0.001), statin treatment for primary prevention (47.9% vs 34.8%, pϽ0.05), and a significant increase in length of time since the last lipid measurement (13.00Ϯ9.36 vs 11.05Ϯ8.03 months, pϽ0.05). Although the average duration of treatment was greater for the failed group (32.7Ϯ20.0 vs 27.7Ϯ15.0 months, pϽ0.05), 71.1% of patients had not had a serum lipid estimation within the preceding 6 months and 40.6% within the preceding year. Despite similar levels of statin usage in both groups (21.1Ϯ10.1 vs 19.4Ϯ7.8mg/day of simvastatin, failed vs met, pϭ0.086) patients in the failed group had a significantly lower response to statin therapy (21.34Ϯ12.80% vs 32.45Ϯ12.10, pϽ0.001) indicating poor patient compliance or the existence of a group of poor responders. To identify factors other than pre-treatment TC which might explain treatment failure, 116 patients were matched for pre-treatment TC (58 met, 58 failed) and data analysed. The only significant difference between these two groups was the response to statin therapy, which was greater in those who had met target (33.6Ϯ7.6% vs 14.1Ϯ9.0%, pϽ0.001).
At the present time we are failing to meet recommended cholesterol targets. The reasons for this are evident from the low doses of statin prescribed (mean 20.15Ϯ8.82mg/day), and failure to measure response appropriately. Pre-treatment TC should determine the starting statin dose which then should be up-titrated according to response. There are also a group of individuals who have a poor response to statin therapy regardless of pre-treatment TC raising the possibility of poor compliance. Although statins may be used in appropriate patients they are not used to achieve optimal CHD risk reduction indicating the need for further doctor and patient education. To compare BP control rates using these recommendations, a chart review was performed. Among the 437 consecutive patients first seen in the Rush University Hypertension Center from September, 1998 to February, 2000 were 86 diabetics (47% male, 61 ϩ 12 years old). The mean initial BP was 156 Ϯ 24/ 89 Ϯ 12 mm Hg and, after at least one year in clinic, decreased to 137 Ϯ 16/ 78 Ϯ 10 mm Hg at the most recent visit. Goal BP achievement varied depending on which guideline criteria were applied.
Overall, diabetic patients reached goal BP less commonly than nondiabetic patients, but the difference was statistically significant only when a lower goal BP was considered for diabetics (P Ͻ 0.001 by chi-square, using either JNC VI or ADA/NKF goals; P ϭ 0.22 for HEDIS criteria). Similarly, the trend for controlled hypertension decreased significantly as the goal BP declined, whether or not the non-diabetics were included in the analyses (all P Ͻ 0.001). This trend was significant for both systolic (chi-square ϭ 25, P Ͻ 0.001) and diastolic BP (chi-square ϭ14, P Ͻ 0.001). Control of systolic BP was less commonly achieved than diastolic, regardless of which goal BP was used (P ϭ 0.025 by chi-square). BP control among diabetics is, therefore, less common when more stringent goals are used, even among patients seen in a specialized Hypertension Center with a high prevalence of controlled hypertension. These data suggest that achieving the recently-recommended lower BP 160A AJH-April 2002-VOL. 15, NO. 4 , PART 2 POSTERS: Guidelines Downloaded from https://academic.oup.com/ajh/article-abstract/15/S3/160A/225935 by guest on 08 March 2019
